FDA advisory panel members face new conflict-of-interest review
New research reviewed 20 years of FDA advisory committee meetings and found that nearly 40% included a patient or consumer representative with active ties to an advocacy organization. The findings raise questions about potential industry influence in the advisory process.
The findings could affect trust among patients, advocates, and regulators who rely on FDA advisory committees. Advisory panel members and advocacy organizations may face greater scrutiny over disclosed ties. Drug developers could also see questions about whether advisory proceedings are perceived as independent. The impact may depend on how regulators and committees respond, but the story may prompt broader discussion about transparency in drug development oversight. Count: The1 findings2 could3 affect4 trust5 among6 patients7, advocates8, and9 regulators10 who11 rely12 on13 FDA14 advisory15 committees16. Advisory17 panel18 members19 and20 advocacy21 organizations22 may23 face24 greater25 scrutiny26 over27 disclosed28 ties29. Drug30 developers31 could32 also33 see34 questions35 about36 whether37 advisory38 proceedings39 are40 perceived41 as42 independent43. The44 impact45 may46 depend47 on48 how49 regulators50 and51 committees52 respond53, but54 the55 story56 may57 prompt58 broader59